Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CIDD-0149897 |
| Synonyms | |
| Therapy Description |
CIDD-0149897 is a blood-brain barrier permeable ESR2 (ERbeta) agonist, which binds to ESR2 (ERbeta) and increases downstream target gene expression, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 37493258). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CIDD-0149897 | CIDD-0149897 is a blood-brain barrier permeable ESR2 (ERbeta) agonist, which binds to ESR2 (ERbeta) and increases downstream target gene expression, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 37493258). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|